Biozen Cuffless Monitor Shows How FDA Uses Consensus Standards in Device Review

Biozen said on May 11 that the Food and Drug Administration had cleared its BP1000, a handheld monitor that takes spot blood pressure readings from the fingertip without an inflatable cuff, through the 510(k) pathway. FDA's 510(k) database entry lists the BP1000 Ultra-Compact Fingertip Blood Pressure Monitor under number K253152, classified as a non-invasive blood pressure measurement system, with a decision of substantially equivalent dated May 6, 2026.

In its announcement, distributed by PR Newswire, the Oklahoma City company said the technology "was validated against ISO 81060-2:2018, the international standard for non-invasive blood pressure devices, demonstrating equivalence to traditional cuff-based reference measurements." The release says the device is intended for spot checks in adults ages 22 to 59 who do not have active arrhythmias such as atrial fibrillation or peripheral artery disease and are not pregnant, and that it needs no per-user calibration against a cuff. Medical Device Network reported that Biozen plans a phased US introduction, with broader availability targeted for late 2026.

The reference to an ISO standard points to a less visible part of how FDA reviews devices: its program for recognizing voluntary consensus standards.

What a consensus standard is

FDA's Division of Standards and Conformity Assessment describes a voluntary consensus standard as one developed or adopted by standards development organizations, domestic and international, under consensus principles. Those bodies must show transparency, openness to participation, balance of representation and due process, which FDA says is why such standards contribute to regulatory quality. ISO 81060-2, which Biozen describes as the international standard for non-invasive blood pressure devices, is published by the International Organization for Standardization.

Using a standard is optional. FDA says manufacturers are encouraged to use FDA-recognized standards in premarket submissions, but that "conformance is voluntary, unless a standard is 'incorporated by reference' into regulation."

Recognition and the declaration of conformity

Recognition is the step that gives a standard regulatory weight. FDA defines it as the process by which the agency identifies standards to which device makers may submit a declaration of conformity to show they have met relevant requirements of the Federal Food, Drug, and Cosmetic Act. FDA may recognize all, part or none of a standard, and any interested party may ask it to recognize one. The agency says it intends to respond to requests within 60 days, publishes its justification for each decision, assigns a recognition number and a supplemental information sheet to each recognized standard, and lists them in its Recognized Consensus Standards Database, with periodic notices in the Federal Register.

A company that chooses to conform to a recognized standard may file a declaration of conformity as part of a 510(k), De Novo request, premarket approval application or other submission. According to FDA, declarations of conformity "may reduce the amount of supporting testing documentation typically needed in a premarket submission." FDA says standards are particularly useful when a recognized standard serves as a complete performance standard for a specific device, and that more general standards can also streamline review. Makers identify the standards they rely on in the cover sheet of the submission.

Limits on what a standard settles

A declaration covers only what the standard covers, and only while recognition stands. FDA says a manufacturer may not submit a declaration of conformity to a non-recognized, superseded or withdrawn standard, though such a standard may still be cited under a general use category. FDA also runs the voluntary Accreditation Scheme for Conformity Assessment, which it says is meant to increase its confidence in declarations of conformity and reduce its requests for more information about test methods.

Neither FDA's database entry nor the release states which parts of Biozen's 510(k) relied on a declaration of conformity. Biozen's description of its ISO 81060-2 validation is the company's own.